Perspective Therapeutics, Inc. (CATX)

Market Cap	90.64M
Revenue (ttm)	9.95M
Net Income (ttm)	-9.10M
Shares Out	142.07M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	415,388
Open	0.610
Previous Close	0.610
Day's Range	0.600 - 0.638
52-Week Range	0.192 - 0.673
Beta	n/a
Analysts	Buy
Price Target	1.02 (+59.88%)
Earnings Date	May 9, 2023

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly know...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 66
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CATX

Financial Performance

In 2022, CATX's revenue was $10.80 million, an increase of 7.38% compared to the previous year's $10.05 million. Losses were -$7.27 million, 114.5% more than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for CATX stock is "Buy." The 12-month stock price forecast is $1.02, which is an increase of 59.88% from the latest price.

Price Target

$1.02

(59.88% upside)

Analyst Consensus: Buy